Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Weekly
Analytics
American chemical industry news
(page 12)
31 October 2025
Iberdrola Acquires PREVI's 30.29% Stake in Neoenergia
Iberdrola now controls 84% of Neoenergia, investing €1.92 billion. Neoenergia leads Brazil's distribution with 40M customers and 3,800 MW renewable capacity.
31 October 2025
LyondellBasell Q3 2025 Earnings Report
Reported net loss of $890M, EBITDA of $(480)M. Cash from operations at $983M. Continued focus on operational improvements, asset sales, and cash management.
31 October 2025
ADNOC Hosts Global Leaders on Energy and AI in Abu Dhabi
Global leaders will discuss AI's role in sustainable growth and energy efficiency at the ENACT Majlis, ahead of ADIPEC in Abu Dhabi.
30 October 2025
Lilly Q3 2025 Financials: Revenue Up 54%, R&D Progress, Guidance Raised
Revenue growth driven by incretin demand. Advanced orforglipron trials, FDA approval for Inluriyo. Expanded manufacturing in Virginia, Texas, Puerto Rico.
30 October 2025
Topsoe Opens Europe's Largest SOEC Facility
The new facility in Denmark will produce high-efficiency electrolyzers for green hydrogen, aiding industrial decarbonization and supported by EU funding.
30 October 2025
Merck Announces Q3 2025 Financial Results
Sales rose 4% to $17.3B. KEYTRUDA up 10%, GARDASIL down 24%. GAAP EPS $2.32, Non-GAAP $2.58. FDA approved KEYTRUDA QLEX. Acquired Verona Pharma. Full-year sales outlook: $64.5B-$65B.
How does the American chemical industry perform?
Find out with
chemXplore Analytics
Learn more
30 October 2025
Technip Energies 9M 2025 Results
Revenue and EBITDA up 9% Y/Y. Acquired Ecovyst's AM&C business. Major LNG contract in the US. Strong outlook in LNG, decarbonization, and sustainable fuels.
30 October 2025
Roche Acquires 89bio Shares in Tender Offer
Roche's subsidiary accepted tendered shares of 89bio, planning a merger to make 89bio a wholly owned subsidiary, delisting it from Nasdaq.
30 October 2025
WACKER Q3 Results Align with Expectations, Adjusts Full-Year Forecast
Q3 sales fell 6% to €1.34B, EBITDA dropped 23% to €112M. Net result was €-82M. Focus on cash and costs. Full-year EBITDA in lower expected range.
30 October 2025
Covestro Q3 2025: Results Meet Expectations, Effective Cost-Cutting
Despite challenges, cost-cutting and strategic investments drive progress. Full-year forecast narrowed; focus on sustainable growth and innovation continues.
29 October 2025
Lilly Invests $1.2 Billion in Puerto Rico for U.S. Oral Medicine Manufacturing Expansion
The investment will create 100 manufacturing and 1,000 construction jobs, enhancing production of oral solid medicines with advanced technologies. Construction starts in 2026, production by 2028.
29 October 2025
Iberdrola Launches €1 Billion EU Green Hybrid Bond
Iberdrola's €1 billion green hybrid bond saw high demand, oversubscribed 8 times, with a 3.75% coupon. It aligns with EU Green Bond Standard, attracting sustainable investors.
29 October 2025
Johnson & Johnson to Conduct Study Comparing IMAAVY™ and Alternative FcRn Blocker for gMG
The EPIC study will compare IMAAVY™ to efgartigimod in gMG patients, including a treatment-switch arm. Vibrance-MG data shows sustained IgG reduction and disease control in pediatric patients.
29 October 2025
Merck and Eisai Update on LEAP-012 Trial for Hepatocellular Carcinoma
The LEAP-012 trial showed no overall survival benefit for the treatment, but progression-free survival improved. The study is closed, and further data analysis is ongoing.
29 October 2025
UPM Q3 2025: Resilient Performance Amid Weak Markets
Sales and EBIT declined. Strategic reviews and partnerships initiated. Plywood and paper production adjustments. Biorefinery progress. Sustainability recognized. Uncertainty persists.
29 October 2025
BASF Q3 2025 Earnings Slightly Exceed Market Expectations
Sales fell 3% due to currency effects and lower prices. EBITDA before special items was €1.5 billion. Share buyback program to start in November 2025.
28 October 2025
Novo Nordisk to Present Wegovy® Data at 2025 AASLD Meeting
11 abstracts on Wegovy® and MASH to be presented at AASLD 2025, highlighting clinical and real-world data, including post-hoc analyses of the ESSENCE trial.
28 October 2025
Merck's KEYTRUDA and WELIREG Combo Improves DFS in RCC Patients Post-Nephrectomy
The LITESPARK-022 trial shows improved DFS with KEYTRUDA and WELIREG in RCC patients. Safety profiles align with previous studies. Results to be shared with regulators.
28 October 2025
Merck and Eisai's WELIREG and LENVIMA Improve PFS in Advanced Renal Cell Carcinoma Trial
The trial showed significant PFS and ORR improvements with WELIREG and LENVIMA in advanced RCC patients post anti-PD-1/L1 therapy, with consistent safety profiles.
28 October 2025
Roche's Gazyva Shows Positive Phase III Results in Pediatric Nephrotic Syndrome
Gazyva achieved sustained remission in young nephrotic syndrome patients, reducing steroid use. No new safety issues. Data to be shared with health authorities.
27 October 2025
Dow's Freeport MDI Facility Achieves ISCC PLUS Certification
The Freeport facility now offers bio-circular isocyanates with ISCC PLUS certification, enhancing sustainability and supply chain transparency for various industries.
27 October 2025
Iberdrola Wins M&A Value Award
Iberdrola's strategic M&A activities, including 26 deals worth over €18.5B, have accelerated its growth, meeting 2026 targets early and boosting its market position.
27 October 2025
Merck's WINREVAIR Approved by FDA for Expanded PAH Treatment
WINREVAIR, now approved for PAH, improves exercise capacity, reduces clinical worsening risks, and shows significant efficacy in the ZENITH trial. Monitor hemoglobin and platelets during treatment.
27 October 2025
Johnson & Johnson's Icotrokinra Shows Therapeutic Benefit and Safety in Ulcerative Colitis
Icotrokinra shows sustained clinical benefits and safety in ulcerative colitis, with Phase 3 trials underway for broader applications.
27 October 2025
Johnson & Johnson Study Highlights Unmet Psoriasis Needs and Preference for Effective Oral Treatments
The ENCOMPASS study shows significant psoriasis burden and preference for oral treatments, highlighting unmet needs in patient care and quality of life impacts.
27 October 2025
Johnson & Johnson's TREMFYA® Shows Two-Year Remission in Crohn's Disease
TREMFYA® maintains remission in Crohn's disease over 96 weeks, with consistent safety and efficacy in both subcutaneous and intravenous regimens.
24 October 2025
Johnson & Johnson: Nipocalimab Reduces Sjögren’s Disease Activity and Severity
Nipocalimab shows promise in reducing Sjögren’s disease symptoms and autoantibodies, with a favorable safety profile and ongoing Phase 3 trials.
24 October 2025
Merus Reports Positive Interim Data on Petosemtamab in Metastatic Colorectal Cancer
Petosemtamab shows promising response rates in 1L and 2L mCRC, with potential as a new standard of care.
24 October 2025
Kemira Oyj Q3 2025: Profitability Steady Amid Market Challenges
Revenue and EBITDA declined due to market softness. Water Solutions remained strong. Strategic acquisitions and partnerships aim to boost growth. 2025 outlook remains unchanged.
24 October 2025
Kemira Acquires Water Engineering, Inc.
The acquisition enhances Kemira's North American market position and water treatment capabilities, integrating Water Engineering, Inc. into its Water Solutions unit.
← Previous
Next →
